Fourier Intelligence

Fourier Intelligence has built a broad rehabilitation robotics platform since its founding in 2015. Originally focused on force feedback technology for therapy devices, the company has expanded into general-purpose humanoid robotics while maintaining its core rehabilitation business under the Fourier Rehab subsidiary.

Company Overview

Founded by Alex Gu (顾捷) and Zen Koh in Shanghai, Fourier Intelligence began with the development of force feedback-based rehabilitation robots. The company launched the Fourier M2 upper limb rehabilitation robot, which it describes as the first commercial product of its kind in China, and subsequently developed the ExoMotus lower limb exoskeleton series. By 2024, Fourier reported serving more than 2,000 institutions across over 40 countries.

In July 2024, the company underwent a strategic rebranding, splitting into two divisions: Fourier, focusing on general-purpose humanoid robots including the GR series, and Fourier Rehab, continuing its rehabilitation robotics mission. This restructuring reflects the company’s dual ambitions in both medical rehabilitation and embodied AI.

The company has completed 12 funding rounds, raising over CNY 1.6 billion cumulatively. Its January 2025 Series E round of approximately CNY 800 million was led by Shanghai state-backed investors including Guoxin Investment, Pudong Venture Capital, and Zhangjiang Science & Technology Investment, with participation from Saudi Aramco’s Prosperity7 Ventures. This gives the company a valuation of approximately CNY 8 billion, making it a unicorn in the robotics sector. In 2025, the company also received strategic investment from listed company Runyang Technology, with an amount not exceeding CNY 300 million at a pre-investment valuation of CNY 8 billion.

Core Products

RehabHub™ Platform

The RehabHub represents Fourier’s integrated approach to rehabilitation, combining multiple robotic systems within a unified digital training environment. The platform supports neurological, orthopedic, and pain management therapies across all recovery stages, with AI-driven data analysis and real-time feedback capabilities.

ExoMotus Lower Limb Exoskeleton

The ExoMotus series provides powered gait training for patients with spinal cord injuries and other lower limb impairments. The system features a torque safety protection mechanism to prevent falls and uses an intelligent modular battery management system for approximately 8 hours of continuous operation. The platform supports integration with AR headsets and EEG devices for enhanced intention control.

ArmMotus Upper Limb Rehabilitation Robot

The ArmMotus M2 was China’s first commercial rehabilitation robot based on force feedback technology. The system provides precise resistance and assistance during upper extremity therapy, with real-time performance tracking and gamified training protocols.

GR Series Humanoid Robots

The GR-1, launched in 2023, marked Fourier’s entry into general-purpose humanoid robotics. Standing 165 cm tall and weighing 55 kg, it features 40 degrees of freedom and can carry loads up to 50 kg. The GR-2, released in September 2024, increased to 175 cm height with 53 degrees of freedom. Over 100 GR-1 units have been delivered for applications including healthcare assistance, academic research, and commercial service.

The GR-3, unveiled at CES 2026 in January, represents Fourier’s first full-size “Care-bot” designed for empathy-driven human-robot interaction. Standing 165 cm tall and weighing 71 kg with 55 degrees of freedom, GR-3 targets applications in homes, public spaces, commercial environments, and assisted living facilities. In April 2025, Fourier also released the Fourier N1, a 1.3-meter open-source humanoid robot weighing 38 kg with 23 degrees of freedom, aimed at accelerating ecosystem development within the robotics industry.

Technology & Innovation

Fourier’s core competency lies in actuator design and force control technology. The company developed the Fourier Smart Actuator (FSA) series, which provides the cost-effective, high-performance actuation essential for both rehabilitation exoskeletons and humanoid robots.

In collaboration with National Instruments and the University of Melbourne, Fourier created EXOPS (Exoskeleton Robot Open Platform), enabling academic and clinical institutions to conduct research and secondary development on exoskeleton systems.

The company’s rehabilitation devices integrate AI-driven training protocols with thorough data collection, supporting evidence-based therapy optimization. The GR humanoid series incorporates large multimodal language models for natural human-robot interaction.

Market Presence

Fourier Rehab maintains a significant international footprint, with products deployed in hospitals, rehabilitation centers, and research institutions across more than 40 countries including the United States, United Kingdom, Germany, Singapore, Australia, and the UAE. The company has established regional offices in Singapore and Malaysia to support international operations.

In the humanoid robotics sector, Fourier positions the GR series for commercial applications including concierge services, healthcare assistance, academic research, and eldercare. The company has deployed robots at banks, automotive dealerships, international conferences, and public venues.

Key Milestones

• 2015: Company founded in Shanghai
• 2017: Launched China’s first commercial lower limb exoskeleton robot
• 2019: Initiated general-purpose humanoid robot development project
• 2022: Completed CNY 400 million Series D round led by SoftBank Vision Fund 2
• 2023: Released GR-1 humanoid robot at World Artificial Intelligence Conference
• 2024: Delivered over 100 GR-1 units; rebranded to Fourier and Fourier Rehab divisions
• 2024: Launched GR-2 with enhanced specifications (September)
• 2025: Completed CNY 800 million Series E round; valuation reached CNY 8 billion (January)
• 2025: Released Fourier N1 open-source humanoid robot (April)
• 2025: Received strategic investment from Runyang Technology (up to CNY 300 million)
• 2026: Unveiled GR-3 full-size Care-bot at CES 2026 (January)

Frequently Asked Questions

What products does Fourier Intelligence offer?

Fourier offers rehabilitation robots including the ExoMotus lower limb exoskeleton, ArmMotus upper limb system, and the RehabHub integrated platform. The company also develops GR series humanoid robots for healthcare, research, and commercial applications.

Is Fourier Intelligence publicly traded?

No, Fourier Intelligence remains a private company. As of January 2025, it has completed 12 funding rounds with a valuation of approximately CNY 8 billion. The company has not announced IPO plans.

How many countries does Fourier operate in?

Fourier’s rehabilitation products are deployed in over 40 countries, serving more than 2,000 institutions globally. The company has regional offices in Singapore and Malaysia supporting international operations.

What is the difference between Fourier and Fourier Rehab?

In July 2024, Fourier Intelligence restructured into two divisions: Fourier focuses on general-purpose humanoid robots (GR series), while Fourier Rehab continues developing rehabilitation robotics including exoskeletons and therapy devices.